Celldex Therapeutics (CLDX) Posts Narrower than Expected Q4 Loss

Celldex Therapeutics (NASDAQ: CLDX) reported Q4 EPS of ($0.24), $0.04 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $2.43 million versus the consensus estimate of $2.26 million.

For earnings history and earnings-related data on Celldex Therapeutics (CLDX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Aeroméxico Announces Webcast of Second Quarter 2026 Financial Results
• Creatd files Form S-1 and reports Q1 2026 financial results